Showing results (1851-1860 of 1,930) with videos related to

Sort By:
Pageof 193
G3 (Bethesda, Md.)|September 12, 2018
Systems Genetics Approach to Biomarker Discovery: GPNMB and Heart Failure in Mice and HumansLiang-Yu Lin, Sunny Chun Chang, Jim O'Hearn, et al.
Journal of Critical Care|May 12, 2019
Application of dynamic pulse pressure and vasopressor tools for predicting outcomes in patients with sepsis in intensive care unitsWen-Feng Fang, Chi-Han Huang, Yu-Mu Chen, et al.
Journal of Clinical Laboratory Analysis|March 25, 2010
Identification of melamine/cyanuric acid-containing nephrolithiasis by infrared spectroscopyWen-Chi Chen, San-Yuan Wu, Hsin-Ping Liu, et al.
Ebiomedicine|July 25, 2016
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal CancerTzu-Tang Wei, Yi-Ting Lin, Wen-Shu Chen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2018
mRNA-binding protein tristetraprolin is essential for cardiac response to iron deficiency by regulating mitochondrial functionTatsuya Sato, Hsiang-Chun Chang, Marina Bayeva, et al.
Nature Communications|April 8, 2025
Vacancy-induced suppression of charge density wave order and its impact on magnetic order in kagome antiferromagnet FeGeMason L Klemm, Saif Siddique, Yuan-Chun Chang, et al.
Cell Reports|December 4, 2014
Telomere elongation and naive pluripotent stem cells achieved from telomerase haplo-insufficient cells by somatic cell nuclear transferLi-Ying Sung, Wei-Fang Chang, Qian Zhang, et al.
The Journal of Investigative Dermatology|May 8, 2014
Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reactionChun-Nan Yeh, Wen-Hung Chung, Shih-Chi Su, et al.
Annals of the Rheumatic Diseases|August 14, 2014
Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysinWen-Hung Chung, Wan-Chun Chang, Sophie L Stocker, et al.
The Lancet. Oncology|April 17, 2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Takayuki Yoshino, Allen Lee Cohn, et al.
Pageof 193